Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2621 - Adjuvant chemotherapy for stage III colorectal cancer in the elderly


08 Oct 2016


Poster Display


Daniel Brungs


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


D. Brungs1, E. Healey2, J. Rose2, T. Tubaro2, W. Ng3, W. Chua4, M. Carolan1, P. de Souza5, M. Aghmesheh1, M. Ranson6

Author affiliations

  • 1 Medical Oncology, Wollongong Hospital, 2500 - Wollongong/AU
  • 2 Medical Oncology, Wollongong Hospital, Wollongong/AU
  • 3 Collaboration For Cancer Outcomes Research And Evaluation (ccore), Ingham Institute for Applied Medical Research, University of New South Wales, Sydney, NSW, Australia, Sydney/AU
  • 4 Medical Oncology, Liverpool Hospital, Sydney/AU
  • 5 Medical Oncology, Western Sydney University School of Medicine, 2170 - Liverpool/AU
  • 6 Illawarra Health And Medical Research Institute, University of Wollongong, Wollongong/AU


Abstract 2621


Colorectal cancer (CRC) is a common and lethal malignancy which is related to aging, with almost 40% of CRC diagnosed above 75 years in both Australia and the United States. Adjuvant chemotherapy is a key treatment in patients with Stage III colorectal cancer, and combination chemotherapy using a fluoropyrimidine and oxaliplatin doublet (such as FOLFOX or XELOX) is the current standard of care, with a 20% reduction in risk of death compared to fluoropyrimidine monotherapy. It is not clear if this benefit is seen in elderly patients in the community setting.


TNM stage, chemotherapy treatment records, and overall survival data was obtained for 2923 patients with stage III colorectal cancer by linkage of New South Wales cancer registry records with data from the births, deaths and marriages registry. To determine the impact of age, two separate cox proportional hazard models were used to compare the effect of combination chemotherapy regimens on overall survival (OS) for patients 70 and older, and younger than 70. Multivariate analysis was performed using a subset of 1008 patients with more complete clinicopathologic data.


Patients in the 70yrs and older age group had poorer OS (5yr OS 58.8 vs 76.7%, HR 0.47 95%CI 0.41 – 0.54, p


Patients 70 years and older, with stage III colorectal, may gain a similar OS benefit with adjuvant oxaliplatin doublet chemotherapy as younger patients. Combination adjuvant chemotherapy should be considered in elderly patients

Clinical trial identification

Legal entity responsible for the study

The Centre for Oncology Education and Research Translation (CONCERT)


The Centre for Oncology Education and Research Translation (CONCERT)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings